Orient Securities Company Limited(600958) underwriting and recommendation Co., Ltd. about
Listing recommendation letter of Suzhou fujilai Pharmaceutical Co., Ltd. for initial public offering and listing on the gem
Shenzhen Stock Exchange:
As the sponsor of Suzhou fujilai Pharmaceutical Co., Ltd. (hereinafter referred to as “fujilai”, “issuer” or “company”) for initial public offering and listing on the gem, Orient Securities Company Limited(600958) underwriting sponsor Co., Ltd. (hereinafter referred to as “Oriental Investment Bank“, “sponsor”) and its sponsor representative have The measures for the administration of securities issuance and listing recommendation business, the measures for the administration of the registration of initial public offerings on the gem (for Trial Implementation) (hereinafter referred to as the “Registration Administration Measures”), the rules for the listing of shares on the gem of Shenzhen Stock Exchange (hereinafter referred to as the “Listing Rules”) Laws and regulations such as the Shenzhen Stock Exchange gem stock issuance and listing review rules and the relevant provisions of the CSRC and Shenzhen Stock Exchange are honest, trustworthy, diligent and responsible, issue the listing recommendation letter in strict accordance with the business rules and industry self-discipline norms formulated according to law, and ensure that the documents issued are true, accurate and complete.
The relevant information about the listing is reported as follows. Unless otherwise specified, the abbreviations or terms in this listing recommendation have the same meanings as those in the prospectus of the company’s initial public offering of shares and listing on the gem. 1、 Basic information of the issuer (I) introduction to the issuer
Company name: Suzhou fujilai Pharmaceutical Co., Ltd
English Name: Suzhou FUSHILAI Pharmaceutical Co, LTD
Registered capital: 68.75 million yuan
Legal representative: Qian Xiangyun
Date of establishment of the company: November 27, 2000
Date of establishment of the joint stock company: November 21, 2013
Registered address: No. 16, Haiwang Road, Changshu new material industrial park, Jiangsu Province
Office address: No. 16, Haiwang Road, Changshu new material industrial park, Jiangsu Province
Postal Code: 215500
Tel: 051252015605
Fax: 051252303736
Internet address: http://www.fuslai.com./
Email: [email protected].
Production and sales: ethyl 6,8-dichlorooctanoate, lipoic acid and derivatives, L-carnosine and derivatives, glycerol phosphatidylcholine, phosphatidylcholine, lipoamide, irecoxib and apatinib; Sales and production of by-products: sodium sulfite, polyaluminium chloride, ammonia (≤ 10%), diketazine; By products of retail production: industrial salt (NaCl content ≥ 96%); Self support and agency of import and export business of various commodities and technologies (business scope of enterprises limited or prohibited by the state: except products and technologies). (for projects subject to approval according to law, business activities can be carried out only after approval by relevant departments). Licensed items: drug production; Import and export of drugs (for items subject to approval according to law, business activities can be carried out only after approval by relevant departments, and the specific business items shall be subject to the approval results). General projects: research and development of biochemical product technology; Engineering and technical research and test development; Technical services, technical development, technical consultation, technical exchange, technology transfer and technology promotion (except for projects that must be approved according to law, business activities shall be carried out independently according to law with business license).
(II) main business
The company is mainly engaged in the R & D, production and sales of pharmaceutical intermediates, APIs and raw materials of health products. Its main products include lipoic acid series, phosphatidylcholine series and carnosine series. Since its establishment, the company’s main business has not changed significantly.
The company has become a global supplier of raw materials and health care products by adhering to the advantages of rigorous production and pragmatic service, and has become an important supplier of raw materials and health care products in recent 20 years. The company’s products are exported to overseas markets such as Europe, America, Japan, South Korea, India and South America, and has established long-term and stable cooperative relations with many downstream pharmaceutical and health products enterprises.
After years of accumulation, the company has formed a rich product structure, including lipoic acid series, phosphatidylcholine series and carnosine series, covering three fields: pharmaceutical intermediates, APIs and raw materials of health products. The company has a drug production license, and has passed the national GMP certification for lipoic acid API and jupri zinc (carnosine series products) API; The raw materials of the company’s health products have passed the review of ISO22000 food safety management system standard, HACCP system and Its Application Guide (CAC / rcp-1-1969, Rev. 4-2003) and other standard systems; The company uses lipoic acid and its derivatives, L-carnosine and its derivatives as raw materials for health products
In 2014, it accepted the on-site inspection of FDA and passed the zero defect inspection; L-carnosine products are used as pharmaceutical intermediates in
In 2015, it passed the on-site inspection of Japan pharmaceutical products and medical devices comprehensive agency (PMDA).
The company is a high-tech enterprise, and was recognized as the “small giant enterprise of science and technology in Jiangsu Province” and “small giant enterprise of science and technology in Jiangsu Province” in 2018
“Suzhou engineering technology research center” and “Suzhou enterprise technology center” master independent intellectual property rights and advanced technology
The production process has obtained 30 invention patents. The company has a complete and professional R & D platform with
Perfect R & D team and continuous R & D investment bring the company effective optimization of product pipeline, so as to maintain the insurance
Maintain the advanced nature of the company’s products and processes.
(III) core technology and R & D level
1. Issuer’s core technology and its source
The issuer always adheres to technological innovation and continuously optimizes the process technology to make the technical level of products and manufacturing workers
The technology level has been continuously improved and reached the advanced level of the industry. As of the signing date of the listing sponsor, the company’s core technology
include:
Brief description of patent acquisition in sequence technology phase acquisition time general / unique number name method technology
Green synthesis technology refers to the treatment of wastewater in the preparation of non-toxic and harmless raw lipoic acid
Zero emission method for industrial and recycling of green compounds and reagents under mild conditions
1. It has the characteristics of low pollution, recyclability and chemical regeneration (Patent No.: R & D 2009 / 12 / 16 general technology, high yield and high quality, and has actually produced 20081 Yanan Bicon Pharmaceutical Listed Company(002411) 10)
It is used in the industrial production of lipoic acid
The technology realizes a high yield and high quality
Synthesis method of industrial L-carnosine suitable for industrial production with good L-carnosine and low energy consumption (patent independent)
2. Compared with the unique technology developed on April 13, 2011 by the same kind of Huasheng No.: 20081 Shenzhen Fastprint Circuit Tech Co.Ltd(002436) 0x), this method has the advantages of low raw material consumption and high yield in reaction steps
Short and high yield
A strain of Rhodococcus and its preparation
Optically pure (R) – 6-hydroxy-8-chlorooctane
This technology obtains 2017 / 9 / 1 from near smooth pseudoacid and other optically active chirality through gene bank
Use of high-performance carbonyl reducing alcohol in Saccharomyces cerevisiae (Patent No.:
Enzymes.
On this basis, carbonyl reduction (201310236252x) was constructed
Gene coexpression of biological enzyme and glucose dehydrogenase
3 method reaction system, recombinant Escherichia coli whole cell as a general technical catalyst for the production of (s) – 6-hydroxy-8-chlorooctanoate ethyl ester, preparation method and application of enzymatic asymmetric reduction of r-lipoxin (patent independent 2019 / 1 / 22)
Research and development of 6-carbonyl-8-chlorooctanoic acid (No.: 201510507587x), the key intermediate of acid
Ethyl ester. The technology has been applied to r-sulfur
Industrial production of caprylic acid
(R)- α Preparation method of lipoic acid 1 / 2 / 5
(Patent No.: R & D)
Brief description of patent acquisition in sequence technology phase acquisition time general / unique number name method technology
2016104111765）
Acidification of ethyl lipoate hydrolysate
Device (Patent No.: 2012 / 5 / 2)
20081 Xinjiang Guotong Pipeline Co.Ltd(002205) 19）；
According to the specific reaction type, the company and the recovery unit of subsequent lipoic acid aqueous solution
Management process, design and actual process requirements (Patent No.: independent 2010 / 9 / 15)
4 specific anti-conforming equipment and devices, so as to realize the matching of R & D general reactor technology with production equipment, so as to improve high yield
economic performance. It has been applied to the synthesis of ethyl 6-carbonyl-8-chlorooctanoate
Device in industrial production and synthesis of 6-carbonyl by the device
Research and development of ethyl 8-chlorooctanoate-
(application No.:
2020100311909）
Preparation of racemic DL, D or D by one-step method
L- α- The method of glycerol phosphorylcholine provides a one-step method for preparing racemic DL
Compared with the existing technology, the technical scheme of GPC operates industrial D or L- α- Glycerol phosphorylcholine
5. The synthesis technology is simple, and the method of external digestion can be obtained in only one step (Patent No.: R & D of DL, D or L, unique technical rotator on April 10, 2013)- α- GPC, solved
